Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanabe
This review aims to provide a comprehensive overview of the current literature on the drug design, development, and therapy of lurasidone for the treatment of schizophrenia. Lurasidone has antagonistic effects on the dopamine D2 , 5-hydroxytryptamine (5-HT)2A , and 5-HT7 receptors and a partial agonistic effect on the 5-HT1A receptor with low affinities for muscarinic M1 , histamine H1 , and a1 adrenergic receptors. The receptor-binding profile of lurasidone is thought to be associated with fewer side effects such as anticholinergic effects, lipid abnormalities, hyperglycemia, and weight gain...
2023: Drug Design, Development and Therapy